Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475550 | 1.00 | CTSK (0.35) | CTSKCA14CA12HDAC6DGAT1 | |
| SCHEMBL23610131 | 0.90 | CTSK (0.33) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL23610132 | 0.90 | CTSK (0.33) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL28381761 | 0.84 | HDAC6 (0.33) | CTSKCA14CA12HDAC6DGAT1 | |
| SCHEMBL16083949 | 0.84 | HDAC6 (0.33) | CTSKCA14CA12HDAC6DGAT1 | |
| SCHEMBL28265179 | 0.83 | CTSK (0.33) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL16982776 | 0.83 | CTSK (0.33) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL28660954 | 0.83 | CTSK (0.33) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL15406527 | 0.82 | HDAC6 (0.32) | CTSKCA14CA12HDAC6HDAC1 | |
| SCHEMBL15406529 | 0.82 | HDAC6 (0.32) | CTSKCA14CA12HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518088-B2 | Peptide-phospholipid conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-17 | — | — | US | disclosed |
| US-20130345117-A1 | PEPTIDE-PHOSPHOLIPID CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012108990-A2 | PEPTIDE-PHOSPHOLIPID CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | AAK1, NCK1, ANKK1 | CTSK 839/4885CA14 4640/4885CA12 4685/4885 |
| US-20130345117-A1 | PEPTIDE-PHOSPHOLIPID CONJUGATES | LPAR3, SSTR3, NPY2R | CTSK 1638/4885CA14 1684/4885CA12 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.